Download PDF
CC BY 4.0 · Osteologie 2020; 29(04): 293-301
DOI: 10.1055/a-1257-8108
Originalarbeit

Diagnostik und Therapie der hypophosphatämischen Rachitis im Kindesalter

Hypophosphatemic Rickets: Diagnostic Approach and current Treatments in Childhood
Jakob Höppner
1   Centrum für seltene Erkrankungen Ruhr, Ruhr-Universität Bochum und Universität Witten/Herdecke, Bochum, Deutschland
,
Uwe Kornak
2   Institut für Humangenetik, Universitätsmedizin Göttingen, Deutschland
,
Wolfgang Högler
3   Univ.-Klinik für Kinder- und Jugendheilkunde, Johannes Kepler Universität Linz, Kepleruniversitätsklinikum, Linz, Österreich
,
Barbara Obermayer-Pietsch
4   Klinische Abteilung Endokrinologie und Diabetologie, Universitätsklinik für Innere Medizin, Medizinische Universität Graz, Österreich
,
Frank Rutsch
5   Allgemeine Pädiatrie, Klinik für Kinder- und Jugendmedizin und Centrum für seltene Erkrankungen, Universitätsklinikum Münster, Deutschland
,
Ralf Oheim
6   Institut für Osteologie und Biomechanik, Universitätsklinikum Hamburg-Eppendorf, Deutschland
,
Corinna Grasemann
1   Centrum für seltene Erkrankungen Ruhr, Ruhr-Universität Bochum und Universität Witten/Herdecke, Bochum, Deutschland
7   Klinik für Kinder- und Jugendmedizin, St. Josef-Hospital, Universitätsklinikum der Ruhruniversität Bochum, Deutschland
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Zusammenfassung

Die Rachitis im Kindes- und Jugendalter beruht auf einer Unterversorgung des wachsenden Körpers mit Kalzium und/oder Phosphat. Der Kalzium-Phosphat-Stoffwechsel unterliegt einer komplexen hormonellen Regulation durch Calcitriol, Parathormon und dem ‚Fibroblast Growth Factor 23‘(FGF23).

Eine unphysiologische Überproduktion von FGF23 führt durch resultierenden renalen Phosphatverlust zu einem Phosphatmangel, mit der Folge der Untermineralisation von Knochen, Zähnen und Wachstumsfugen und damit zur hypophosphatämischen Rachitis (HR) bzw. Osteomalazie. Die häufigste Form der FGF23-abhängigen HR ist die X-chromosomale hypophosphatämische Rachitis (XLH). Im Kindesalter steht, neben einer Substitution von Phosphat und aktivem Vitamin D, mit Burosumab seit 2018 ein monoklonaler Antikörper gegen FGF23 für die Therapie der XLH zur Verfügung. Diese Therapie hat das Potenzial, Langzeitkomplikationsraten, Wachstum und Lebensqualität substanziell zu verbessern, entsprechende Langzeitdaten werden daher in Registern gesammelt.

Möglichkeiten zur Vernetzung mit Betroffenen bieten die Vereine Phosphatdiabetes e.V. und www.phosphatdiabetes.at.

Abstract

Rickets is caused by an undersupply of calcium and/or phosphate to the growing body. The calcium-phosphate metabolism is regulated by the secosteroid hormone calcitriol, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23).

Excessive FGF23 action results in reduced renal phosphate reabsorption, and subsequent hypophosphataemia, undermineralization of bone, teeth and growth plates and the phenotype of hypophosphatemic rickets (HR)/osteomalacia. The most common form of FGF23-dependent HR is X-linked hypophosphatemic rickets (XLH), which was traditionally treated via supplementation of phosphate and active vitamin D only. Since 2018, a monoclonal antibody against FGF23, Burosumab, is available for the therapy of XLH in children. The new therapy has the potential to improve long-term complications, growth and quality of life; such data are currently being collected in registries. Support groups for German-speaking people affected by XLHinclude Phosphatdiabetes e.V. and www.phosphatdiabetes.at.

Schlüsselwörter

Phosphat-Stoffwechsel - FGF23 - Hypophosphatämische Rachitis - Phosphatdiabetes - Osteomalazie, Burosumab

Key words

Phosphate metabolism - FGF23 - hypophosphatemic rickets - burosumab


Publication History

Article published online:
23 November 2020

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Bauer DC. Calcium supplements and fracture prevention. N Engl J Med 2013; 369 (16) : 1537-1543
    CrossrefPubMedSearch in Google Scholar
  • 2 Crombie JL, Venkateswaran R, Kim AS. et al. Bad to the bone. N Engl J Med 2019; 381 (04) : e9
    CrossrefPubMedSearch in Google Scholar
  • 3 Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357 (03) : 266-281
    CrossrefPubMedSearch in Google Scholar
  • 4 Gafni RI, Collins MT. Hypoparathyroidism. N Engl J Med 2019; 380 (18) : 1738-1747
    CrossrefPubMedSearch in Google Scholar
  • 5 Liu S, Quarles LD. How fibroblast growth factor 23 works. J Am Soc Nephrol 2007; 18 (06) : 1637-1647
    CrossrefPubMedSearch in Google Scholar
  • 6 Vervloet M. Renal and extrarenal effects of fibroblast growth factor 23. Nat Rev Nephrol 2019; 15 (02) : 109-120
    CrossrefPubMedSearch in Google Scholar
  • 7 Razzaque MS, Lanske B. The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol 2007; 194 (01) : 1-10
    CrossrefPubMedSearch in Google Scholar
  • 8 Erben R. Physiologie und Pathophysiologie von FGF23 und Klotho. Der Nephrologe 2019; 14 (04) : 302-304
    CrossrefSearch in Google Scholar
  • 9 Carpenter TO. Shaw NJ, Portale AA et al. Rickets. Nat Rev Dis Primers 2017; 3: 17101
    CrossrefPubMedSearch in Google Scholar
  • 10 Uday S, Högler W. Spot the silent sufferers: A call for clinical diagnostic criteria for solar and nutritional osteomalacia. J Steroid Biochem Mol Biol 2019; 188: 141-146
    CrossrefPubMedSearch in Google Scholar
  • 11 Christodoulou C, Cooper C. What is osteoporosis?. Postgrad Med J 2003; 79 (929) : 133-138
    CrossrefPubMedSearch in Google Scholar
  • 12 Oheim R, Hiort O. Hereditäre hypophosphatämische Rachitis. Medizinische Genetik 2019; 31 (04) : 357-363
    CrossrefSearch in Google Scholar
  • 13 Alizadeh Naderi AS, Reilly RF. Hereditary disorders of renal phosphate wasting. Nat Rev Nephrol 2010; 6 (11) : 657-665
    PubMedSearch in Google Scholar
  • 14 Carpenter TO, Imel EA, Holm IA. et al. A clinician’s guide to X-linked hypophosphatemia. J Bone Miner Res 2011; 26 (07) : 1381-1388
    CrossrefPubMedSearch in Google Scholar
  • 15 Carpenter TO, Whyte MP, Imel EA. et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med 2018; 378 (21) : 1987-1998
    CrossrefPubMedSearch in Google Scholar
  • 16 White KE, Evans WE, O'Riordan JLH. et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000; 26 (03) : 345-348
    CrossrefPubMedSearch in Google Scholar
  • 17 Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rickets/osteomalacia: Clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 1997; 82 (02) : 674-681
    CrossrefPubMedSearch in Google Scholar
  • 18 Razzaque MS. The FGF23-Klotho axis: Endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol 2009; 5 (11) : 611-619
    CrossrefPubMedSearch in Google Scholar
  • 19 Farrow EG, Davis SI, Ward LM. et al. Molecular analysis of DMP1 mutants causing autosomal recessive hypophosphatemic rickets. Bone 2009; 44 (02) : 287-294
    CrossrefPubMedSearch in Google Scholar
  • 20 Oheim R, Zimmerman K, Maulding ND. et al. Human heterozygous ENPP1 deficiency is associated with early onset osteoporosis, a phenotype recapitulated in a mouse model of Enpp1 deficiency. J Bone Miner Res 2020; 35 (03) : 528-539
    CrossrefPubMedSearch in Google Scholar
  • 21 Tieder M, Modai D, Samuel R. et al. Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med 1985; 312 (10) : 611-617
    CrossrefPubMedSearch in Google Scholar
  • 22 Lorenz-Depiereux B, Benet-Pages A, Eckstein G. et al. Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 2006; 78 (02) : 193-201
    CrossrefPubMedSearch in Google Scholar
  • 23 Beck-Nielsen SS, Brusgaard K, Rasmussen LM. et al. Phenotype presentation of hypophosphatemic rickets in adults. Calcif Tissue Int 2010; 87 (02) : 108-119
    CrossrefPubMedSearch in Google Scholar
  • 24 Verge CF, Cowell CT, Howard NJ. et al. Growth in children with X-linked hypophosphataemic rickets. Acta Paediatr Suppl 1993; 388: 70-5; discussion 76
    Search in Google Scholar
  • 25 Högler W, Kapelari K. Oral iron for prevention and treatment of rickets and osteomalacia in autosomal dominant hypophosphatemia. J Bone Miner Res 2020; 35 (02) : 226-230
    CrossrefPubMedSearch in Google Scholar
  • 26 Imel EA, Liu Z, Coffman M. et al. Oral iron replacement normalizes fibroblast growth factor 23 in iron-deficient patients with autosomal dominant hypophosphatemic rickets. J Bone Miner Res 2020; 35 (02) : 231-238
    CrossrefPubMedSearch in Google Scholar
  • 27 Lorenz-Depiereux B, Schnabel D, Tiosano D. et al. Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophosphatemic rickets. Am J Hum Genet 2010; 86 (02) : 267-272
    CrossrefPubMedSearch in Google Scholar
  • 28 Kremke B, Bergwitz C, Ahrens W. et al. Hypophosphatemic rickets with hypercalciuria due to mutation in SLC34A3/NaPi-IIc can be masked by vitamin D deficiency and can be associated with renal calcifications. Exp Clin Endocrinol Diabetes 2009; 117 (02) : 49-56
    PubMedSearch in Google Scholar
  • 29 Vlot MC, den Heijer M, de Jongh RT. et al. Clinical utility of bone markers in various diseases. Bone 2018; 114: 215-225
    CrossrefPubMedSearch in Google Scholar
  • 30 Ito N, Fukumoto S, Takeuchi Y. et al. Comparison of two assays for fibroblast growth factor (FGF)-23. J Bone Miner Metab 2005; 23 (06) : 435-440
    CrossrefPubMedSearch in Google Scholar
  • 31 Haffner D, Emma F, Eastwood DM. et al. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol 2019; 15 (07) : 435-455
    CrossrefPubMedSearch in Google Scholar
  • 32 Rothenbuhler A, Schnabel D, Högler W. et al. Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH). Metabolism 2020; 103s: 153892
    PubMedSearch in Google Scholar
  • 33 Seikaly MG, Baum M. Thiazide diuretics arrest the progression of nephrocalcinosis in children with X-linked hypophosphatemia. Pediatrics 2001; 108 (01) : E6
    CrossrefPubMedSearch in Google Scholar
  • 34 Turan S, Aydin C, Bereket A. et al. Identification of a novel dentin matrix protein-1 (DMP-1) mutation and dental anomalies in a kindred with autosomal recessive hypophosphatemia. Bone 2010; 46 (02) : 402-409
    CrossrefPubMedSearch in Google Scholar
  • 35 Tieder M, Arie R, Bab I. et al. A new kindred with hereditary hypophosphatemic rickets with hypercalciuria: Implications for correct diagnosis and treatment. Nephron 1992; 62 (02) : 176-181
    CrossrefPubMedSearch in Google Scholar
  • 36 Sharkey MS, Grunseich K, Carpenter TO. Contemporary medical and surgical management of X-linked hypophosphatemic rickets. J Am Acad Orthop Surg 2015; 23 (07) : 433-442
    CrossrefPubMedSearch in Google Scholar
  • 37 Popkov A, Aranovich A, Popkov D. Results of deformity correction in children with X-linked hereditary hypophosphatemic rickets by external fixation or combined technique. Int Orthop 2015; 39 (12) : 2423-2431
    CrossrefPubMedSearch in Google Scholar
  • 38 Sung KH, Chung CY, Lee KM. et al. Determining the best treatment for coronal angular deformity of the knee joint in growing children: A decision analysis. Biomed Res Int 2014; 2014: 603432
    PubMedSearch in Google Scholar
  • 39 Saran N, Rathjen KE. Guided growth for the correction of pediatric lower limb angular deformity. J Am Acad Orthop Surg 2010; 18 (09) : 528-536
    CrossrefPubMedSearch in Google Scholar
  • 40 Tagliabracci VS, Engel JL, Wiley SE. et al. Dynamic regulation of FGF23 by Fam20C phosphorylation, GalNAc-T3 glycosylation, and furin proteolysis. Proc Natl Acad Sci U S A 2014; 111 (15) : 5520-5525
    CrossrefPubMedSearch in Google Scholar
  • 41 Feng JQ, Ward LM, Liu S. et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 2006; 38 (11) : 1310-1315
    CrossrefPubMedSearch in Google Scholar